Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma

Cancer Letters

Volumn 378, Issue 2, 2016, Pages 87-96

  Lang, Mingxiao ^a   Wang, Xiuchao ^a   Wang, Hongwei ^a   Dong, Jie ^a   Lan, Chungen ^a   Hao, Jihui ^a   Huang, Chongbiao ^a   Li, Xin ^a   Yu, Ming ^a   Yang, Yanhui ^a   Yang, Shengyu ^b   Ren, He ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Arsenic trioxide; Combination treatment; Pancreatic ductal adenocarcinoma; PX 478; Reactive oxygen species

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ARSENIC TRIOXIDE; HYPOXIA INDUCIBLE FACTOR 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; 2-AMINO-3-(4'-N,N-BIS(2-CHLOROETHYL)AMINO)PHENYLPROPIONIC ACID N-OXIDE; ANTINEOPLASTIC AGENT; FOXO1 PROTEIN, HUMAN; HEAT SHOCK PROTEIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUSTARD GAS DERIVATIVE; ORGANOARSENIC DERIVATIVE; OXIDE; PHENYLPROPIONIC ACID DERIVATIVE; SESN3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; OXIDATIVE STRESS; PANCREATIC NEOPLASMS; PATHOLOGY; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSCRIPTION INITIATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; BINDING SITES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FORKHEAD BOX PROTEIN O1; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, NUDE; MUSTARD COMPOUNDS; OXIDATIVE STRESS; OXIDES; PANCREATIC NEOPLASMS; PHENYLPROPIONATES; PROMOTER REGIONS, GENETIC; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969523773     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.016     Document Type: Article

References (52)

1. Checker R., Gambhir L., Sharma D., Kumar M., Sandur S.K. Plumbagin induces apoptosis in lymphoma cells via oxidative stress mediated glutathionylation and inhibition of mitogen-activated protein kinase phosphatases (MKP1/2). Cancer Lett 2015, 357:265-278.
2. Sullivan L.B., Chandel N.S. Mitochondrial reactive oxygen species and cancer. Cancer Metab 2014, 2:17.
3. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10:241-252.
4. Jin S.Y., Lee H.S., Kim E.K., Ha J.M., Kim Y.W., Bae S. Reactive oxygen species and PI3K/Akt signaling in cancer. Free Radic. Biol. Med 2014, 75(Suppl. 1):S34-S35.
5. Ciscato F., Sciacovelli M., Villano G., Turato C., Bernardi P., Rasola A., et al. SERPINB3 protects from oxidative damage by chemotherapeutics through inhibition of mitochondrial respiratory complex I. Oncotarget 2014, 5:2418-2427.
6. Lu J., Tan M., Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett 2015, 356:156-164.
7. Ding S., Li C., Cheng N., Cui X., Xu X., Zhou G. Redox regulation in cancer stem cells. Oxid. Med. Cell. Longev 2015, 2015:750798.
8. Di Pietro C., Piro S., Tabbi G., Ragusa M., Di Pietro V., Zimmitti V., et al. Cellular and molecular effects of protons: apoptosis induction and potential implications for cancer therapy. Apoptosis 2006, 11:57-66.
9. Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition 2013, 29:15-21.
10. Ibanez I.L., Notcovich C., Catalano P.N., Bellino M.G., Duran H. The redox-active nanomaterial toolbox for cancer therapy. Cancer Lett 2015, 359:9-19.
11. Hao J. HIF-1 is a critical target of pancreatic cancer. Oncoimmunology 2015, 4:e1026535.
12. Brasiuniene B., Juozaityte E., Brasiunas V., Inciura A. [The update on pancreatic cancer chemotherapy]. Medicina 2003, 39:1016-1025.
13. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett 2012, 317:127-135.
14. Wang R., Liu C., Xia L., Zhao G., Gabrilove J., Waxman S., et al. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin. Cancer Res 2012, 18:6690-6701.
15. Li W., Wang M., Wang L., Ji S., Zhang J., Zhang C. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cell Biochem. Biophys 2014, 68:427-436.
16. Noh E.K., Kim H., Park M.J., Baek J.H., Park J.H., Cha S.J., et al. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Leuk. Res 2010, 34:1501-1505.
17. Wang W., Adachi M., Zhang R., Zhou J., Zhu D. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas 2009, 38:e114-e123.
18. Zepeda A.B., Pessoa A., Castillo R.L., Figueroa C.A., Pulgar V.M., Farias J.G. Cellular and molecular mechanisms in the hypoxic tissue: role of HIF-1 and ROS. Cell Biochem. Funct 2013, 31:451-459.
19. Hong S.S., Lee H., Kim K.W. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res. Treat 2004, 36:343-353.
20. Loboda A., Jozkowicz A., Dulak J. HIF-1 and HIF-2 transcription factors-similar but not identical. Mol. Cells 2010, 29:435-442.
21. Mimura I., Tanaka T., Wada Y., Kodama T., Nangaku M. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: epigenetic regulation of the hypoxic response via hypoxia-inducible factor and histone modifying enzymes. J. Pharmacol. Sci 2011, 115:453-458.
22. Zhao T., Gao S., Wang X., Liu J., Duan Y., Yuan Z., et al. Hypoxia-inducible factor-1alpha regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene. PLoS ONE 2012, 7. e43399.
23. Kirito K., Hu Y., Komatsu N. HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1. Cell Cycle 2009, 8:2844-2849.
24. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-185.
25. Ozel Turkcu U., Tekin N.S., Edgunlu T.G., Karakas S.C., Oner S. The association of Foxo3a gene polymorphisms with serum Foxo3a levels and oxidative stress markers in vitiligo patients. Gene 2013, 10.1016/S0378-1119(13)00039-5.
26. Chen C.C., Jeon S.M., Bhaskar P.T., Nogueira V., Sundararajan D., Tonic I., et al. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Dev. Cell 2010, 18:592-604.
27. Hagenbuchner J., Ausserlechner M.J. Mitochondria and FOXO3: breath or die. Front. Physiol 2013, 4:147.
28. Bakker W.J., Harris I.S., Mak T.W. FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol. Cell 2007, 28:941-953.
29. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther 2008, 7:90-100.
30. Li J.J., Tang Q., Li Y., Hu B.R., Ming Z.Y., Fu Q., et al. Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid. Acta Pharmacol. Sin 2006, 27:1078-1084.
31. Tian Y.Y., Jiang B., An L.J., Bao Y.M. Neuroprotective effect of catalpol against MPP(+)-induced oxidative stress in mesencephalic neurons. Eur. J. Pharmacol 2007, 568:142-148.
32. Xiao W., Jiang Y., Men Q., Yuan L., Huang Z., Liu T., et al. Tetrandrine induces G1/S cell cycle arrest through the ROS/Akt pathway in EOMA cells and inhibits angiogenesis in vivo. Int. J. Oncol 2015, 46:360-368.
33. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett 2008, 266:12-20.
34. Nogueira V., Park Y., Chen C.C., Xu P.Z., Chen M.L., Tonic I., et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470.
35. McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci 2011, 31:15703-15715.
36. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
37. Gong J., Munoz A.R., Chan D., Ghosh R., Kumar A.P. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 2014, 5:2529-2541.
38. Chen C.N., Wu C.L., Lin J.K. Apoptosis of human melanoma cells induced by the novel compounds propolin A and propolin B from Taiwenese propolis. Cancer Lett 2007, 245:218-231.
39. Kiessling M.K., Klemke C.D., Kaminski M.M., Galani I.E., Krammer P.H., Gulow K. Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 2009, 69:2365-2374.
40. Long Z.J., Hu Y., Li X.D., He Y., Xiao R.Z., Fang Z.G., et al. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. PLoS ONE 2014, 9. e104610.
41. Han B., Zhou G., Zhang Q., Zhang J., Wang X., Tang W., et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J. Exp. Ther. Oncol 2004, 4:335-342.
42. Nakaoka T., Ota A., Ono T., Karnan S., Konishi H., Furuhashi A., et al. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol 2014, 37:119-129.
43. Chiu H.W., Lin W., Ho S.Y., Wang Y.J. Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis. Radiat. Res 2011, 175:547-560.
44. Li Y.N., Xi M.M., Guo Y., Hai C.X., Yang W.L., Qin X.J. NADPH oxidase-mitochondria axis-derived ROS mediate arsenite-induced HIF-1alpha stabilization by inhibiting prolyl hydroxylases activity. Toxicol. Lett 2014, 224:165-174.
45. Song J., Yoon D., Christensen R.D., Horvathova M., Thiagarajan P., Prchal J.T. HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis. J. Mol. Med 2015, 93:857-866.
46. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122.
47. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
48. Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S., Baek J.H., Wesley J.B., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem 2008, 283:10892-10903.
49. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
50. Hagenbuchner J., Kuznetsov A., Hermann M., Hausott B., Obexer P., Ausserlechner M.J. FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3. J. Cell Sci 2012, 125:1191-1203.
51. Wang P., Zhu C.F., Ma M.Z., Chen G., Song M., Zeng Z.L., et al. Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. Oncotarget 2015, 6:21148-21158.
52. Cheng G., Lanza-Jacoby S. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: role of NOX4. Biochem. Biophys. Res. Commun 2015, 465:41-46.